The purpose of this study is to find ways to improve wound healing and decrease the negative effects of trauma from burn injury.
This study involves research and the investigators hope to learn the following: how or what effect one or more anabolic ("tissue building") agents have on muscle metabolism, wound healing, and immune function after severe burn. The agents include the following: growth hormone, insulin-like growth factor-1 in combination with its binding proteins, insulin, Beta-adrenergic blockers, Alpha Adrenergic Agonist, anabolic steroids such as testosterone, Oxandrolone and nandrolone, ketoconazole and its derivatives, dehydroepiandrosterone, fenofibrate, diet or the application of skin substitute.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
644
Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
Oxandrolone given daily throughout hospitalization until 95% wound healing.
University of Texas Medical Branch
Galveston, Texas, United States
Decrease Hypermetabolism as Measured by Stable Isotope Infusion Study
At the request of the study site, this study has been closed. Access to study-related data is unavailable, and the PI is no longer at the institution. Hence, we are unable to submit the results data. Although peer-reviewed articles have been located that reference NCT00673309, it is not clear and verifiable (without access to the actual study-related data) what the results for the study outcomes are.
Time frame: Admission to burn unit to 95% wound healing
Improved Rate of Wound Healing
At the request of the study site, this study has been closed. Access to study-related data is unavailable, and the PI is no longer at the institution. Hence, we are unable to submit the results data. Although peer-reviewed articles have been located that reference NCT00673309, it is not clear and verifiable (without access to the actual study-related data) what the results for the study outcomes are.
Time frame: Admission to burn unit to 95% wound healing
Incidence of Morbidity and Mortality
At the request of the study site, this study has been closed. Access to study-related data is unavailable, and the PI is no longer at the institution. Hence, we are unable to submit the results data. Although peer-reviewed articles have been located that reference NCT00673309, it is not clear and verifiable (without access to the actual study-related data) what the results for the study outcomes are.
Time frame: Admission to burn unit to discharge
Incidence of Sepsis
At the request of the study site, this study has been closed. Access to study-related data is unavailable, and the PI is no longer at the institution. Hence, we are unable to submit the results data. Although peer-reviewed articles have been located that reference NCT00673309, it is not clear and verifiable (without access to the actual study-related data) what the results for the study outcomes are.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Propranolol to be given daily throughout hospitalization until 95% wound healing.
Recombinant Human Growth hormone to be administered daily until 95% wound healing.
Insulin administered IV until 95% wound healing
Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
Itraconazole administered until 95% wound healing
Growth Hormone and Propranolol given until 95% wound healing
Oxandrolone and Propranolol
Administration of Placebo or Control until 95% wound healing
Time frame: Admission to burn unit to 95% wound healing